Dolph Houben

26 CHAPTER 1 83. Ildstad, S.T. and D.H. Sachs, Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature, 1984. 307 : p. 168. 84. Adams, D.H. and I.V. Hutchinson, Microchimerism and graft tolerance: cause or effect? Lancet, 1997. 349 (9062): p. 1336-7. 85. Kawai, T. and D. Sachs, Tolerance induction: hematopoietic chimerism. Curr Opin Organ Transplant, 2013. 18 (4): p. 402-7. doi: 10.1097/MOT.0b013e328363621d. 86. Starzl, T.E., A.J. Demetris, M. Trucco, et al., Systemic chimerism in human female recipients of male livers. Lancet, 1992. 340 (8824): p. 876-7. 87. Larsen, M., M. Pelzer, P.F. Friedrich, et al., Living bone allotransplants survive by surgical angiogenesis alone: development of a novel method of composite tissue allotransplantation. Journal of Bone & Joint Surgery - American Volume, 2011. 93 (3): p. 261-73. 88. Ashton-Chess, J., S. Brouard, and J.P. Soulillou, Is clinical tolerance realistic in the next decade? Transpl Int., 2006. 19 (7): p. 539-48. doi: 10.1111/j.1432-2277.2006.00339.x. 89. Todo, S., K. Yamashita, R. Goto, et al., A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology., 2016. 64 (2): p. 632-43. doi: 10.1002/hep.28459. Epub 2016 Mar 10. 90. Hara, M., C.I. Kingsley, M. Niimi, et al., IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol., 2001. 166 (6): p. 3789-96. 91. Elster, E.A., P.J. Blair, and A.D. Kirk, Potential of costimulation-based therapies for composite tissue allotransplantation. Microsurgery, 2000. 20 (8): p. 430-4. 92. Larsen, C.P., E.T. Elwood, D.Z. Alexander, et al., Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature, 1996. 381 (6581): p. 484-8. 93. Ozer, K., R. Oke, R. Gurunluoglu, et al., Induction of tolerance to hind limb allografts in rats receiving cyclosporine A and antilymphocyte serum: effect of duration of the treatment. Transplantation, 2003. 75 (1): p. 31-6. 94. Foster, R.D., N.L.M. Ascher, T.H., M. Neipp, et al., Mixed allogeneic chimerismas a reliablemodel for composite tissue allograft tolerance induction across major and minor histocompatibility barriers. Transplantation, 2001. 72 (5): p. 791-7. 95. Foster, R.D., L. Fan, M. Neipp, et al., Donor-specific tolerance induction in composite tissue allografts. Am J Surg, 1998. 176 (5): p. 418-21. 96. Gammie, J.S., S. Li, Y.L. Colson, et al., A partial conditioning strategy for achieving mixed chimerism in rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. Exp Hematol, 1998. 26 : p. 927. 97. Hewitt, C.W., R. Llull, and M.P. Pate, Mechanisms of unresponsiveness associated with pretransplant blood transfusion-cyuclosporine-induced mixed lymphocyte chimerism. Transplant International, 1994. 7 : p. S559. 98. Monaco, A.P. and M.L. Wood, Studies on heterologous antilymphocyte serum: VII. Optimal cellular antigen for induction of immunological tolerance with antilymphocyte serum. Transplant Proc, 1970. 2 : p. 459. 99. Burdick, J.F., G.B. Vogelsang, W.J. Smith, et al., Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med, 1988. 318 (11): p. 689-91. 100. Kernan, N.A., G. Bartsch, R.C. Ash, et al., Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med, 1993. 328 (9): p. 593-602. 101. Korngold, B. and J. Sprent, Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med, 1978. 148 (6): p. 1687-98. 102. Muramatsu, K., R. Kuriyama, H. Kato, et al., Prolonged survival of experimental extremity allografts: a new protocol with total body irradiation, granulocyte-colony stimulation factor, and FK506. J Orthop Res., 2010. 28 (4): p. 457-61. doi: 10.1002/jor.21011.